News Archive
OptiBiotix launches WellBiome study with Hull NHS trust
24th Feb 2026 15:44
(Sharecast News) - OptiBiotix Health announced the start of a clinical study with Hull University Teaching Hospitals NHS Trust on Tuesday, to assess whether its 'WellBiome' prebiotic could improve cardiac surgery outcomes and deliver potential cost savings for the NHS.
Read moreUS consumer confidence improves more than expected in February
24th Feb 2026 15:30
(Sharecast News) - US consumer confidence improved more than expected in February, according to a survey released on Tuesday.
Read moreN$ Pharma appoints new CEO, proposes name change
24th Feb 2026 15:13
(Sharecast News) - N4 Pharma announced the appointment of Dr David H Solomon as its chief executive on Tuesday, and unveiled plans to rebrand as Thalia Therapeutics as it pivoted towards becoming an RNA therapeutics-focused biotechnology company.
Read moreFTSE 250 movers: Raspberry Pi surges; Unite slumps
24th Feb 2026 15:11
(Sharecast News) - FTSE 250 (MCX) 23,527.60 -0.08%
Read moreNovo Nordisk slashes US prices for Wegovy, Ozempic as competition ramps up
24th Feb 2026 14:55
(Sharecast News) - Danish pharma giant Novo Nordisk is to halve the US price of obesity drug Wegovy and slash the price of diabetes treatment Ozempic from next year as competition ramps up with rival drugmaker Eli Lilly.
Read moreFTSE 100 movers: Convatec surges on guidance upgrade; banks fall
24th Feb 2026 14:51
(Sharecast News) - London's FTSE 100 was 0.2% higher at 10,708.32 in afternoon trade on Tuesday.
Read moreAndrada subsidiary UTMC extends offtake deal with Thaisarco
24th Feb 2026 13:39
(Sharecast News) - Andrada Mining announced the extension of its exclusive offtake agreement with Thailand Smelting & Refining on Tuesday, securing a $3m unsecured advance to support the scaling of operations at its Uis mine in Namibia.
Read moreAndrada subsidiary UTMC extends offtake deal with Thaisarco
24th Feb 2026 13:39
(Sharecast News) - Andrada Mining announced the extension of its exclusive offtake agreement with Thailand Smelting & Refining on Tuesday, securing a $3m unsecured advance to support the scaling of operations at its Uis mine in Namibia.
Read moreReddit fined more than £14m by UK regulator
24th Feb 2026 13:30
(Sharecast News) - Social media platform Reddit has been fined more than £14m for failing to protect the privacy of children, the regulator confirmed on Tuesday.
Read moreFiinu confirms delay to Plugin Overdraft launch with Conister Bank
24th Feb 2026 13:30
(Sharecast News) - Fiinu said on Tuesday that the planned launch of its 'Plugin Overdraft' product with Manx Financial Group and subsidiary Conister Bank was now expected in the second quarter of 2026, reflecting final development requirements.
Read moreTen Lifestyle secures new multi-year contract
24th Feb 2026 13:27
(Sharecast News) - Ten Lifestyle Group announced on Tuesday that it has secured a new multi-year contract with a leading financial services provider in the AMEA region, further strengthening its position in the high and ultra-high net worth segment.
Read moreTPXimpact upgrades full-year EBITDA guidance
24th Feb 2026 13:24
(Sharecast News) - TPXimpact upgraded its full-year EBITDA guidance on Tuesday, after strong third-quarter trading and confirmed more than £110m of new business secured year to date, as the group approached the end of its current three-year turnaround plan.
Read moreAcuity RM to supply more services to Sopra Steria
24th Feb 2026 13:20
(Sharecast News) - Acuity RM Group announced on Tuesday that it has secured a £75,000 contract to supply additional services to Sopra Steria in support of a British government cyber security programme.
Read moreMeta to buy up to $60bn of AMD's AI chips
24th Feb 2026 13:04
(Sharecast News) - Meta Platforms is to buy up to $60bn of AI chips from Advanced Micro Devices in a five-year deal that could see the social network giant take a 10% stake in the semiconductor company.
Read moreAvacta upbeat on preCISION comparative study
24th Feb 2026 12:56
(Sharecast News) - Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages over the marketed antibody drug conjugate Enhertu, as it prepared to begin a phase one trial of its lead programme AVA6103 in the first quarter of 2026.
Read more